Whole Exome Sequencing for Biomarkers Discovery

Whole Exome sequencing (WES) is efficient in discovering novel gene biomarkers in clinical evaluation. Based on the comprehensive analysis of WES data from our cutting-edge SuPrecision™, Creative Biolabs is proficient in developing genome-based biomarkers to guide precision cancer treatment. We can provide a rigorous proof of principle for developing a precision medicine approach to clinical cancer care with the capability to identify novel biomarkers of response and therapeutic targets.

The Background of Cancer Therapy

The rapid development of next-generation sequencing (NGS) analyses providing an unprecedented potential to reach personalized medicine has revolutionized biomedical research and cancer genomics. NGS has provided enormous insight into the genomic landscape of several tumor types, illuminating molecularly defined tumor subtypes, identifying new druggable targets, and providing insights into the heterogeneity of many tumors. WES analyses in tumor-normal tissue pair samples have become a fast and accurate method for sequencing approximate genes of human exome and identifying cancer driver genes for each cancer type. Although advances have been made in decisive therapies, including tumor node metastasis staging therapy based nonspecific multimodal therapy and single-gene testing for identifying mutated or amplified genes, the progress is still slow in fighting against cancer. Although trastuzumab for HER2-positive advanced or metastatic gastric cancer increases response rate and improves overall survival, there’s still an urgently need of robust biomarkers to predict therapeutic resistance. With rapidly advancing technologies and decreasing costs, the use of genomic information to select the most effective treatment options for patients and minimize adverse effects will soon become routinely feasible.

Biomarkers Identification Service at Creative Biolabs

Creative Biolabs has developed an evidence-based precision medicine analysis approach for patients with a tumor or treatment-resistant disease. WES is performed in matched tumor-normal tissues. A comprehensive computational pipeline has been developed and validated by our seasoned scientists for the analysis of WES data. We can provide a comprehensive understanding on how WES affects therapeutic decision making and to identify novel biomarkers of response.

Key Advantages of Biomarkers Identification Service at Creative Biolabs Include but Are Not Limited to:

• One-stop solution for WES projects
• A comprehensive computational pipeline
• Cutting-edge SuPrecision™
• Detailed project report

Creative Biolabs provides a one-stop solution for WES projects from experimental design to advanced bioinformatics analysis. By identifying cancer driver genes involved in tumorigenesis, WES analysis in Creative Biolabs enables the development of robust biomarkers and novel therapeutic targets to reach precision cancer treatment. Our scientists can provide the best service for the identification of novel biomarkers at the most competitive price.

Please contact us for more information and a detailed quote.

Reference

1. Beltran, H.; et al. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. JAMA Oncol. 2015, 1(4):466-74.

1. Tumor Mutational Burden (TMB) Analysis for Response to Checkpoint Immunotherapy
2. Whole Exome Sequencing for Variants Analysis
3. Whole Exome Sequencing for Structural Variants Detection
4. Whole Exome Sequencing for Copy-Number Variants (CNVs) Detection
5. Whole Exome Sequencing for Tumor-Specific Neoantigens Discovery
6. Personal Tumor-Specific Neoantigen Vaccine Development
7. Minimal Residual Disease (MRD) Monitoring Service
8. Microsatellite Instability Analysis for Immunotherapy
9. Tumor Microenvironment Analysis by RNA-Seq
10. Immune Repertoire Germline Genes and Alleles Identification
11. One-stop Service for Cancer 3D Model
12. Circle-Seq-based eccDNA Identification